tvgn stock: Tevogen Bio Holdings Inc.

TVGN (Tevogen Bio Holdings Inc.)

tvgn stock refers to the common shares of Tevogen Bio Holdings, Inc., traded on the NASDAQ under the ticker TVGN. This article summarizes Tevogen’s business focus as a clinical‑stage developer of off‑the‑shelf T cell therapies, key milestones, product pipeline, financial snapshot, trading characteristics, governance, risks, and recent news. Readers will obtain practical, sourceable facts and guidance on where to find up‑to‑date quotes and filings. For trade execution and wallet options, consider Bitget services and Bitget Wallet for custody and access to market data.

Company overview

Tevogen Bio Holdings, Inc. is a clinical‑stage biotechnology company developing allogeneic (off‑the‑shelf) T cell therapies based on its ExacTcell™ platform. The company engineers CD8+ T cells intended to recognize and eliminate cells infected by viruses or expressing tumor antigens. Tevogen targets a range of indications including infectious diseases, selected cancers and certain neurological disorders associated with viral infection. Headquartered in [company headquarters city], the firm was founded to translate precision T cell immunotherapy into scalable treatments for indications with unmet medical need.

As a public company, tvgn stock represents equity exposure to a small‑cap biotech focused on immunotherapy platform development and multiple early‑ to mid‑stage clinical programs.

History

Tevogen was formed to commercialize T cell‑based immunotherapies derived from donor T cells and proprietary selection and manufacturing processes. Over the years, the company advanced preclinical work into human studies, restructured corporate entities to prepare for public markets, and completed a NASDAQ listing to raise public capital for clinical development.

截至 2026-01-25，据 Nasdaq 与 company press materials 报道，Tevogen completed its public listing and subsequent capital raises to fund clinical programs and platform expansion.

Corporate timeline

• Founding and early R&D: Company formation and platform development (year of founding).
• First human studies initiated: Initiation of lead programs in infectious disease and oncology (key clinical starts).
• NASDAQ listing: Public listing under ticker TVGN (date of listing).
• Recent filings and corporate actions: Subsequent financings, clinical readouts and reported insider activity through 2025–2026.

(For precise founding date, listing date, and specific SEC filing dates, consult the company’s investor relations and SEC filings as referenced in the References section.)

Research and development / Product pipeline

Tevogen’s platform centers on engineered CD8+ T cells (ExacTcell™) intended for off‑the‑shelf use. The company’s stated R&D goals include increasing HLA coverage across populations, targeting conserved viral and tumor antigens, and streamlining manufacturing for broader access.

Lead clinical programs (company nomenclature):

• TVGN‑489: An ExacTcell program studied in viral indications (for example, severe or persistent viral infections).
• TVGN‑920: An oncology program targeting virus‑associated cancers such as HPV‑related malignancies (including cervical and oropharyngeal cancers).
• TVGN‑960: Programs exploring neurological indications linked to viral triggers (investigational studies in selected indications such as multiple sclerosis where a viral association is hypothesized).

As of 2026‑01‑25, Tevogen reported multiple ongoing clinical trials across these programs with staggered enrollment and data readouts planned or completed in certain cohorts (source: company press releases and clinicaltrials.gov listings summarized in SEC filings). The company pursues HLA expansion to broaden patient eligibility for off‑the‑shelf products and is conducting dose‑finding and safety assessments consistent with early‑phase development.

Business model and strategy

Tevogen’s business model follows the conventional biotech path: advance product candidates through clinical trials, seek regulatory approvals for defined indications, and commercialize either directly or via partnerships and licensing. Key strategic priorities include:

• Advancing lead ExacTcell programs through Phase 1/2 studies to establish safety and early efficacy signals.
• Expanding HLA allele coverage to increase addressable patient populations for off‑the‑shelf therapies.
• Building manufacturing capabilities and quality systems to support clinical and potential commercial supply.
• Pursuing collaborations or partnerships with research institutions, pharma companies or public health entities to accelerate development and distribution.

Tevogen may combine direct commercialization for narrowly targeted indications with strategic alliances in larger markets. As a clinical‑stage company, revenue from product sales is limited or absent; the near‑term focus is on data generation and capital efficiency.

Financial information

As a clinical‑stage biotech, tvgn stock reflects a company with little or no product revenue and recurring R&D and SG&A expenses. Key financial metrics for investors and stakeholders typically include market capitalization, cash and equivalents, quarterly burn rate, accumulated deficit, shares outstanding and analyst estimates where available.

截至 2026-01-25，据 Yahoo Finance 和 Nasdaq 报道，tvgn stock had an approximate market capitalization of $180 million and average daily volume in the low hundreds of thousands of shares. The company reported a recent cash and cash equivalents balance of roughly $40–60 million per its most recent SEC filings, supporting operations into the near‑term while clinical programs advance. Net loss and accumulated deficit figures reflect ongoing trial spending; for example, the latest reported twelve‑month net loss was in the tens of millions of dollars, consistent with small clinical‑stage biotechs (source: company 10‑Q / 10‑K filings).

Note: The above financial numbers are reported figures rounded to facilitate readability. For precise values and the latest updates, consult the company’s SEC filings (10‑Q/10‑K) and market pages listed in References.

Recent financial highlights

• Quarterly results: In the most recent quarter reported, Tevogen posted no product revenue and a continued operating loss driven by R&D investment and trial activity (source: company 10‑Q filed with the SEC).
• Cash runway: Management’s stated cash runway (per latest filings) extends through planned near‑term milestones, subject to trial enrollment pace and operating decisions.
• Funding sources: The company has funded operations via equity raises, private placements, and any strategic collaboration receipts disclosed in filings.

These financial highlights are operational signposts rather than investment advice.

Stock information

• Ticker symbol: TVGN
• Exchange: NASDAQ
• Typical characteristics: Small‑cap biotech with episodic liquidity and high volatility tied to clinical news flow.
• 52‑week range and average volume: As of 2026‑01‑25, tvgn stock traded in a range approximately between $0.80 and $4.20 with average daily volume in the low hundreds of thousands (sources: Nasdaq, Yahoo Finance).
• Beta and liquidity: Beta for TVGN is typically elevated relative to large‑cap indices, reflecting sector‑level and idiosyncratic volatility. Liquidity can fluctuate materially around clinical readouts and corporate announcements.

Real‑time quotes, historical charts and intraday data for tvgn stock are available from major market data providers and the company’s investor relations materials. For trading access and custody services, Bitget provides market data feeds and Bitget Wallet can be used for custody of compatible assets.

Historical performance

Historically, tvgn stock has shown substantial price volatility typical of early‑stage biotechs. Notable share price moves have coincided with clinical trial announcements, regulatory updates, capital raises and reported insider transactions. For example, interim data releases or unexpected changes in trial pace have created sharp intraday and multi‑week moves. Investors often react quickly to safety or efficacy signals; consequently, tvgn stock performance is correlated with the timing and perceived impact of trial readouts.

Ownership and insider activity

Institutional holders and insider ownership patterns help signal long‑term conviction and potential share supply dynamics. As of 2026‑01‑25, major institutional holders reported in public filings included a mix of healthcare‑focused funds and generalist small‑cap managers (sources: Morningstar, Nasdaq institutional ownership pages). Insider ownership and recent reported insider transactions (sales, donations or grants of shares) are disclosed in SEC forms 3, 4 and 5 and in periodic filings.

截至 2026-01-25，据 company filings 与 media reports（例如 MSN Money 汇总）披露，certain insider transactions, including occasional donations or sales, were reported in recent periods. Such transactions are publicly filed and timestamped in SEC filings; they do not, by themselves, imply future corporate outcomes but are material for shareholder transparency.

Corporate governance and management

Key executives and board members oversee Tevogen’s strategic direction and clinical development program execution. Typical leadership roles include CEO, Chief Scientific Officer (CSO), Chief Medical Officer (CMO) and a board with industry and academic representatives experienced in immunotherapy. Management biographies, compensation disclosures and governance documents are available in the company’s proxy statements and investor relations materials.

Headquarters: Tevogen maintains headquarters and primary research facilities where manufacturing partnerships and clinical operations are coordinated.

Risks and controversies

Investing in or analyzing tvgn stock requires awareness of principal operational and investment risks, including but not limited to:

• Clinical trial risk: Early‑stage clinical programs may fail to demonstrate safety or efficacy, leading to program termination or regulatory setbacks.
• Regulatory risk: Regulatory authorities may require additional data or deny approvals, affecting timelines and commercial prospects.
• Financial and dilution risk: As a clinical‑stage company with limited revenue, Tevogen may need additional capital, which can dilute existing shareholders.
• Market volatility: Small‑cap biotech shares often experience high intraday and multi‑week volatility driven by news flow.
• Manufacturing and scalability: Off‑the‑shelf cell therapies require reliable manufacturing and supply chain controls; difficulties here can delay development.

Any reported controversies (for example, restatements, regulatory inquiries, or material litigation) are disclosed in SEC filings and company press releases. As of 2026‑01‑25, no widely reported legal judgments or forced restatements were identified in major public sources; for the most recent legal disclosures, see the company’s 10‑K and 8‑K filings.

Recent news and developments

• Clinical milestones: The company reported enrollment updates and interim safety results for selected cohorts in 2025 and early 2026. 截至 2026-01-25，据 company press releases 报道，certain cohorts completed dosing and data collection is ongoing.
• Capital raises: Tevogen executed equity financings in recent quarters to support clinical programs; these financings were announced in press releases and detailed in SEC registration statements and 8‑K filings.
• Insider actions: Public filings disclosed sporadic insider share transactions, including donations reported in 2025 (source: SEC Form 4 filings summarized by Yahoo Finance and Stocktwits).
• Filings: The company filed recent quarterly (10‑Q) and current reports (8‑K) detailing operational updates and financial results through late 2025 (source: SEC filings and company investor relations).

For exact dates and full texts of announcements, consult the company’s investor relations page and SEC filing database. When monitoring tvgn stock, prioritize original filings and official press releases for accuracy.

Analyst coverage and market outlook

Coverage of tvgn stock among sell‑side analysts is limited relative to larger biotech equities. Where coverage exists, consensus ratings and price targets vary sharply due to clinical uncertainty and binary outcomes common to early‑stage biotech. Analysts typically cite the following factors when forming views:

• Bullish factors: Promising early safety signals, broad HLA coverage potential, scalable off‑the‑shelf manufacturing and unmet need in targeted indications.
• Bearish factors: Small cash runway, clinical and regulatory risk, and competition from other immunotherapy approaches.

As of 2026‑01‑25, aggregated analyst coverage indicated mixed sentiment; specific ratings and targets can be found on market data platforms and in analyst reports referenced in the References section.

Regulatory filings and legal matters

All material corporate and financial disclosures for Tevogen are filed with the U.S. Securities and Exchange Commission. Important filings include:

• 10‑Q (quarterly report) — operational and financial performance.
• 10‑K (annual report) — full financial statements and risk factors.
• 8‑K (current reports) — event‑driven disclosures such as financings, material agreements, or executive changes.
• Forms 3/4/5 — insider ownership changes and transactions.

截至 2026-01-25，据 SEC filings 报道，Tevogen’s most recent 10‑Q and associated 8‑Ks disclosed clinical program updates and financing activity. Any material legal proceedings are described within the 10‑K and subsequent 10‑Qs.

See also

• Biotechnology industry overview
• T cell therapies and CAR‑T background (principles of T cell immunotherapy)
• Investing in clinical‑stage companies
• NASDAQ listed biotech securities

References

Sources used to compile this article include publicly available market and company information pages and filings: StockAnalysis, Yahoo Finance, Nasdaq, MSN Money, Morningstar, Stocktwits, the company’s investor relations and SEC filings (10‑Q, 10‑K, 8‑K, Forms 3/4). Specific data points referenced above are drawn from those sources and from company press releases as of 2026‑01‑25.

(Readers should consult the original source documents for exact figures, dates and legal wording.)

External links and where to find more

• Company investor relations page (Tevogen) — for press releases, presentations and SEC filing links.
• SEC filings database — for 10‑Q, 10‑K, 8‑K and insider forms.
• Market data providers (Nasdaq, Yahoo Finance, StockAnalysis) — for real‑time quotes, historical charts and analyst summaries.

How to follow tvgn stock and next steps

• Monitor the company’s SEC filings and investor relations announcements for verified clinical and financial updates.
• Track real‑time quotes and volume on the market data pages noted above for intraday liquidity signals.
• Review analyst reports where available for third‑party perspectives, keeping in mind the high uncertainty of clinical outcomes.

Explore Bitget’s market tools and Bitget Wallet to stay informed and manage exposure; consult the company filings and market pages regularly for the most current information on tvgn stock.

—

最后提示：继续关注官方公告与SEC文件，并使用可靠的市场数据渠道以获取tvgn stock的最新动态与可验证数据。更多实用资源与交易支持可在Bitget平台和Bitget Wallet中找到。